» Articles » PMID: 38582917

Cellular and Molecular Mechanisms of Aspartoacylase and Its Role in Canavan Disease

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2024 Apr 6
PMID 38582917
Authors
Affiliations
Soon will be listed here.
Abstract

Canavan disease is an autosomal recessive and lethal neurological disorder, characterized by the spongy degeneration of the white matter in the brain. The disease is caused by a deficiency of the cytosolic aspartoacylase (ASPA) enzyme, which catalyzes the hydrolysis of N-acetyl-aspartate (NAA), an abundant brain metabolite, into aspartate and acetate. On the physiological level, the mechanism of pathogenicity remains somewhat obscure, with multiple, not mutually exclusive, suggested hypotheses. At the molecular level, recent studies have shown that most disease linked ASPA gene variants lead to a structural destabilization and subsequent proteasomal degradation of the ASPA protein variants, and accordingly Canavan disease should in general be considered a protein misfolding disorder. Here, we comprehensively summarize the molecular and cell biology of ASPA, with a particular focus on disease-linked gene variants and the pathophysiology of Canavan disease. We highlight the importance of high-throughput technologies and computational prediction tools for making genotype-phenotype predictions as we await the results of ongoing trials with gene therapy for Canavan disease.

Citing Articles

Urine -Acetylaspartate Distinguishes Phenotypes in Canavan Disease.

Nagy A, Eichler F, Bley A, Bredow J, Fay A, Townsend E Hum Gene Ther. 2024; 36(1-2):45-56.

PMID: 39628365 PMC: 11807896. DOI: 10.1089/hum.2024.168.

References
1.
Arun P, Moffett J, Namboodiri A . Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells. Neurochem Int. 2009; 55(4):219-25. DOI: 10.1016/j.neuint.2009.03.003. View

2.
Ahmed S, Li H, Cao C, Sikoglu E, Denninger A, Su Q . A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. Mol Ther. 2013; 21(12):2136-47. PMC: 3863789. DOI: 10.1038/mt.2013.138. View

3.
Klugman S, Gross S . Ashkenazi Jewish screening in the twenty-first century. Obstet Gynecol Clin North Am. 2010; 37(1):37-46. DOI: 10.1016/j.ogc.2010.01.001. View

4.
Namboodiri A, Moffett J, Arun P, Mathew R, Namboodiri S, Potti A . Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol. 2006; 576:145-63. DOI: 10.1007/0-387-30172-0_10. View

5.
Matalon R, Rady P, Platt K, Skinner H, Quast M, Campbell G . Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med. 2000; 2(3):165-75. DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<165::AID-JGM107>3.0.CO;2-R. View